Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

Sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Study ID
NCT00845104
Phase
PHASE2
Status
Withdrawn

Conditions

  • B-cell Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • fludarabine phosphate — DRUG
    Given IV
  • rituximab — BIOLOGICAL
    Given IV
  • bevacizumab — BIOLOGICAL
    Given IV
  • laboratory biomarker analysis — OTHER
    Correlative studies
  • flow cytometry — OTHER
    Correlative studies
  • polymerase chain reaction — GENETIC
    Correlative studies
  • fluorescence in situ hybridization — GENETIC
    Correlative studies

Study Details

RATIONALE: Drugs used in chemotherapy, such as fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab and bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving fludarabine phosphate together with rituximab and bevacizumab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving fludarabine phosphate together with rituximab and bevacizumab works in treating patients with B-cell chronic lymphocytic leukemia that has relapsed or not responded to treatment.

Key Dates

Start date
Jan 31, 2009
Status verified
Mar 2015

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    See Detailed Description

Primary Outcome Measure

Progression-free survival [ Time Frame: At 2 years ]

Related Studies